Evogene Ltd. (EVGN) 股票分析

公司概述

Evogene Ltd. operates as a computational biology company with a global footprint spanning Israel, the United States, Europe, and Africa, delivering solutions across agriculture, human health, and industrial application segments. Situated within the healthcare sector and specifically the biotechnology industry, the firm leverages computational methods to drive innovation in seed technologies and other biological applications. The company's current market capitalization stands at $8.11M, while its trailing twelve-month revenue is recorded at $3.85M, with employee count data unavailable in the provided dataset. These valuation and revenue figures indicate that Evogene is a micro-cap entity with a relatively small financial footprint, suggesting a position where it is likely sensitive to market fluctuations and heavily dependent on the successful commercialization of its specific computational biology products within its diverse geographic operations.

财务健康

The company reported a revenue of $3.85M over the trailing twelve months, yet this generated a net income loss of $14,157,000 and an EBITDA of $-13,264,000, revealing a significant disconnect between top-line activity and profitability. The substantial gap between the $3.85M revenue and the -$14.157M net income highlights a cost structure where expenses, including likely heavy R&D and operational costs, vastly exceed current earnings potential. Furthermore, the free cash flow stands at $-17,494,624, indicating that the company is burning cash rapidly, which limits its immediate financial flexibility and necessitates reliance on existing cash reserves or external capital. The margins reflect this financial strain, with a gross margin of -6.3%, an operating margin of -1581.5%, and a profit margin of -220.2%, all of which signal that the company is currently operating at a loss at every level of its P&L statement. On the balance sheet, the company holds $12.96M in cash against $2.20M in debt, resulting in a debt-to-equity ratio of 18.36, which suggests a leveraged position despite the high cash balance. Liquidity appears robust in the short term given a current ratio of 4.54, implying ample ability to meet short-term obligations with current assets. However, the return on equity is -100.7% and the return on assets is -28.8%, metrics that reveal management is currently unable to generate positive returns on the capital invested or assets held.

估值评估

Valuation multiples for Evogene are distorted by its lack of profitability, showing a P/E ratio (TTM) as N/A and a forward P/E of -1.03, implying that earnings are negative and traditional profitability-based valuation models are not applicable. The price-to-book ratio is listed as -91.12, a figure that indicates the market is pricing the company significantly below its book value, often a characteristic of distressed or highly speculative biotech stocks with negative net tangible assets. Alternative metrics such as the price-to-sales ratio of 2.11 and an EV/EBITDA of -0.71 suggest that investors are valuing the firm primarily on its revenue generation potential rather than earnings or cash flow. In terms of trading range, the stock has a 52-week high of $2.42 and a 52-week low of $0.72, providing a context for price volatility within the last year. The beta value of 0.95 indicates that the stock's price volatility moves in line with the broader market, suggesting it does not exhibit extreme sensitivity to market swings compared to high-beta biotech peers.

Growth & Income

Revenue growth year-over-year has contracted sharply by -80.5%, while earnings growth is N/A due to the absence of positive earnings, implying that the company is contracting financially rather than expanding its top line. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the firm retains all of its negative or positive earnings to fund operations and research. The absence of a dividend yield and a payout ratio of 0.0% confirms that the company reinvests all available resources, however limited, into growth initiatives rather than returning capital to shareholders. Overall, the growth and income profile of Evogene Ltd. is characterized by significant revenue contraction, negative earnings, and a reliance on capital preservation rather than income distribution or stable growth.